Romidepsin and metformin nanomaterials delivery on streptozocin for the treatment of Alzheimer's disease in animal model

Biomedicine & Pharmacotherapy

Yeqing Zou¹  Hongmei Zeng²  Lijun Xu²  Sixiang Wang³ 

[1] Corresponding author.;Department of Neurology, the Second Affiliated Hospital of Nanchang University, Nanchang 330006, China;Jiangxi Provincial Key Laboratory of Molecular Medicine, the Second Affiliated Hospital of Nanchang University, Nanchang 330006, China;

关键词: Alzheimer's disease;    Combination therapy;    Neuroprotective;    Nanoformulation;    In vivo animal model;   

DOI  :  

来源: DOAJ

【 摘 要 】

Brain insulin signal anomalies are implicated in Alzheimer's disease (AD) pathology. In this background, metformin, an insulin sensitizer's neuroprotective effectiveness, has been established in the prior findings. In the present investigation, combining an epigenetic modulator, romidepsin, and metformin will improve the gene expressions of neurotrophic factors and reduce AD-associated biochemical and cellular changes by loading them mainly into a nanocarrier surface-modified framework for improved therapeutic effectiveness and bioavailability. In the present investigation, the mediated intra-cerebroventricular streptozocin (3 mg/kg) AD of the model was loaded with metformin and romidepsin into a poloxamer stabilized polymer nanocarrier system. Free combination drug therapy (Romidepsin 25 mg/kg and metformin 5 mg/kg) reduced biochemical and cellular variations over three weeks, respectively, compared to either free treatment (Romidepsin 50 mg/kg and metformin 10 mg/kg). The nanoformulations (Romidepsin 25 mg/kg and Metformin 5 mg/kg), as shown by enhanced significantly reduce stress and high neurotrophic factors, has also exerted superior neurological effectiveness than the free combination of drugs. Eventually, through the Poloxamer stable polymeric nanocarrier framework, the synergistic neuroprotective efficacy of metformin and romidepsin has improved.

【 授权许可】

Unknown